Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Thermo Fisher Scientific insider Michel Lagarde has filed a Form 144 indicating his intent to sell company stock. The notice covers 22,046 shares of common stock to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 12424320.59. The filing notes that 375708059 shares of common stock were outstanding.
Lagarde has also sold Thermo Fisher common shares in recent months. The notice lists sales of 4638 shares on 11/13/2025 for gross proceeds of 2756934.80, 30000 shares on 12/02/2025 for 17457612.00, and 32000 shares on 12/03/2025 for 18668515.20. By signing the notice, the seller represents that he is not aware of any material adverse, nonpublic information about the company’s current or prospective operations.
Thermo Fisher Scientific executive Thomas B. Shropshire, Jr., who serves as SVP and General Counsel, reported a change in his holdings of the company’s common stock. On 12/02/2025, he disposed of 337.476 shares of Thermo Fisher common stock in a transaction coded “F” at a price of $580.37 per share. After this transaction, he beneficially owned 5,079.524 shares, held directly.
Thermo Fisher Scientific executive Frederick M. Lowery, an Executive Vice President, reported option exercises and related stock sales in early December 2025. On December 1, 2025, he exercised 6,913 stock options at $253.99 per share and sold 6,913 shares of common stock at $597.68 per share. On December 2, 2025, he exercised an additional 6,912 options at $253.99 and sold 6,912 shares at $581.94 per share. After these transactions, he directly owned 14,367.3724 shares of Thermo Fisher common stock, with additional indirect holdings of 1,175.83 shares through a 401(k) plan and 5.036 shares through a limited liability company. The transactions were carried out under a Rule 10b5-1 trading plan adopted on August 28, 2025.
TMO insider Michel Lagarde filed a notice to sell 32,000 shares of common stock, with an aggregate market value of 18,668,514.70, through Fidelity Brokerage Services on the NYSE.
The table lists 375,708,059 shares of the issuer’s common stock as outstanding. Over the past three months, Lagarde previously sold 4,638 shares for gross proceeds of 2,756,934.80 and 30,000 shares for gross proceeds of 17,457,612.00.
Thermo Fisher Scientific insider Michel Lagarde filed a notice to sell 30,000 shares of common stock under Rule 144. The planned sale is through Fidelity Brokerage Services on the NYSE, with an aggregate market value of 17,457,611.41 based on the figures provided.
The shares relate to an option originally granted on 07/20/2016 and acquired on 12/02/2025, with payment made in cash. Lagarde also sold 4,638 common shares in a prior transaction on 11/13/2025, generating gross proceeds of 2,756,934.80.
Thermo Fisher Scientific insider plans NYSE sale of option shares. A holder has filed a notice to sell 6,912 shares of Thermo Fisher Scientific common stock on the NYSE through Fidelity Brokerage Services. The shares were acquired on 12/02/2025 via the cash exercise of a stock option originally granted on 02/26/2019. Based on the filing, the aggregate market value of the planned sale is $4,022,369.28. The filing also notes that 375,708,059 common shares were outstanding and that the same seller disposed of 6,913 common shares on 12/01/2025 for gross proceeds of $4,131,761.84.
Thermo Fisher Scientific Inc., through its finance subsidiary Thermo Fisher Scientific (Finance I) B.V., issued €1,000,000,000 of Floating Rate Senior Notes due 2027 and €1,100,000,000 of 3.628% Senior Notes due 2035 in a public offering, fully and unconditionally guaranteed on a senior unsecured basis by the company. The notes were issued under an existing indenture and a new supplemental indenture, with quarterly interest on the floating rate notes and annual interest on the fixed rate notes.
The 2035 fixed rate notes are redeemable before a September 1, 2035 par call date at a make-whole redemption price and at par thereafter, and both series include a change-of-control put at 101% of principal plus accrued interest if the company undergoes a qualifying change of control with concurrent ratings downgrades. The company expects net proceeds of approximately €2.09 billion and intends to use them for general corporate purposes, including potential acquisitions, debt repayment or refinancing, working capital, capital spending, and share repurchases, or for temporary investment in short-term liquid instruments.
A shareholder of Thermo Fisher Scientific has filed a notice of proposed sale of 6,913 shares of common stock under Rule 144. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $4,131,761.84 at the time of the notice. The filing lists an approximate sale date of 12/01/2025. These shares were acquired on 12/01/2025 through the cash exercise of an option that was originally granted on 02/26/2019. As context, the filing reports 375,708,059 shares of the issuer’s common stock outstanding.
Thermo Fisher Scientific Inc. (TMO) executive vice president Michael D. Shafer reported option exercises and related stock sales. On November 25, 2025, he exercised stock options for 8,475 shares at $253.99 and 2,250 shares at $294.02, then sold the same amounts of common stock at $600 per share.
These transactions were carried out under a Rule 10b5-1 trading plan adopted on November 20, 2024. After the reported trades, Shafer directly beneficially owned 18,730.8026 shares of Thermo Fisher common stock, and the exercised options reported in this filing no longer remain outstanding.
Thermo Fisher Scientific (Finance I) B.V., fully guaranteed by Thermo Fisher Scientific Inc., is issuing €2,100,000,000 of senior euro-denominated notes, split between €1,000,000,000 floating rate notes due 2027 and €1,100,000,000 3.628% fixed rate notes due 2035. The floating notes pay 3‑month EURIBOR plus 0.280% with a zero floor and quarterly interest, while the fixed notes pay annual interest at 3.628%. Both issues are unsecured senior obligations and rank equally with other senior unsecured debt of the issuer and guarantor.
The notes are offered at 100% of principal, with underwriting discounts of 0.200% on the floating notes and 0.400% on the fixed notes, generating estimated net proceeds of about €2.09 billion. Thermo Fisher intends to use the cash for general corporate purposes, including potential acquisitions, debt repayment, capital spending, working capital or share repurchases, and may invest proceeds temporarily in short-term instruments. The company also highlights a pending $8.875 billion cash acquisition of Clario Holdings and a recent $2.48 billion U.S. dollar notes offering, underscoring ongoing balance sheet and strategic activity.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
